Clinical Trials · NCT07349641
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 55
- Start date
- Jul 2026
- Locations
- 3 sites, United States
- Primary endpoint
- Weighted pathological complete response (pCR)